Alluvi Retatrutide 20mg (Triple-Agonist) Research Pen – UK Stock

Original price was: £150.00.Current price is: £130.00.

Retatrutide 20mg (High-Potency Triple-Agonist) - UK Stock

Our 20mg Retatrutide research pen offers the perfect concentration for mid-tier laboratory protocols. As a potent GLP-1, GIP, and Glucagon receptor agonist, this triple-agonist is verified at 99%+ purity for reliable R&D data.
  • UK-to-UK Shipping: Dispatched from our UK warehouse (No customs).
  • Certified Quality: Batch-specific CoA provided with every 20mg pen.
  • Triple-Agonist Action: Targeted research for metabolic & endocrine studies.
  • Strictly for Laboratory R&D Use Only.

Alluvi Retatrutide 20mg – High-Stability Research Format

The Alluvi Retatrutide 20mg formulation is specifically designed for researchers requiring high-purity GGG receptor agonists. Unlike standard GLP-1s, Retatrutide’s triple-action mechanism (Glucagon, GIP, and GLP-1) allows for more complex metabolic modeling.

Why Choose Our 20mg Research Pens?

When sourcing Retatrutide 20mg in the UK, consistency is vital. Impure peptides can lead to skewed experimental results.

Buy Retatrutide 20mg UK online

At Alluvi, we utilize advanced lyophilization and cold-chain logistics to ensure your 20mg pens arrive with maximum bio-activity. Each device is calibrated for laboratory precision, making it the gold standard for UK-based independent research.
Technical Data:
  • Molecular Formula: C₂₂₁H₃₄₂N₄₆O₆₈
  • Molecular Weight: 4731.33 g/mol
  • Purity: ≥99.4% HPLC Verified
  • Format: Multi-dose 20mg research pen

 FAQ

Q: Can I buy Retatrutide 20mg for research in the UK?
A: Yes, Alluvi provides Retatrutide 20mg pens specifically for laboratory R&D. We offer domestic UK shipping to ensure researchers receive high-purity peptides without international customs interference

Reviews

There are no reviews yet.

Be the first to review “Alluvi Retatrutide 20mg (Triple-Agonist) Research Pen – UK Stock”

Your email address will not be published. Required fields are marked *